TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric and Young Adult Hematopoietic Stem Cell Transplant Patients

What this Trial Is About

Researchers are studying lung injury in children and young adults undergoing hematopoietic stem cell transplantation (HSCT), which is a treatment for various blood and immune system disorders. Lung complications such as diffuse alveolar hemorrhage, thrombotic microangiopathy, interstitial pneumonitis, and bronchiolitis obliterans can cause serious illness and even death after HSCT. This observational study aims to better understand how often these lung injuries occur, what causes them, and how to improve diagnosis and treatment, especially in young patients who cannot perform standard breathing tests. This is a prospective, multi-institutional study involving pediatric and young adult patients who receive either allogeneic or autologous HSCT. Researchers will assemble a large group of patients who will be uniformly screened over time. Biological samples will be collected to help identify the mechanisms of lung injury and support the development of earlier diagnostic methods and novel treatments to reduce lung-related problems after transplant. Participants will be followed for at least 24 months after their transplant to track the incidence of lung injury. The study involves regular assessments including clinical monitoring and collection of biological samples. The main outcome measured is the occurrence of lung injury within two years post-transplant. This long-term follow-up will provide important information on early and late pulmonary complications, helping to improve care for children and young adults receiving HSCT.

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients